Noble Trims PT on TherapeuticsMD (TXMD) to $17.50 Following Q4 Results; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
TherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:02 PM ESTCompany to Present additional positive phase 3 data for TX-004HR at the ISSWSH annual meeting
Management to host conference call today at 4:30 p.m. EST
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its fourth quarter and full year financial results for 2015.
2015 and Recent Developments
Net revenue for the companys prescription prenatal vitamin business increased to approximately $20.1 million in 2015 compared with approximately $15.0 million for the prior year. Net... More